- Home
- FRPH vs DCTH Comparison
FRPH vs DCTH Comparison
Compare FRPH & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRPH
- DCTH
- Stock Information
- Founded
- FRPH 1986
- DCTH 1988
- Country
- FRPH United States
- DCTH United States
- Employees
- FRPH N/A
- DCTH N/A
- Industry
- FRPH Real Estate
- DCTH Medical/Dental Instruments
- Sector
- FRPH Finance
- DCTH Health Care
- Exchange
- FRPH Nasdaq
- DCTH Nasdaq
- Market Cap
- FRPH 589.9M
- DCTH 518.0M
- IPO Year
- FRPH N/A
- DCTH N/A
- Fundamental
- Price
- FRPH $30.75
- DCTH $14.88
- Analyst Decision
- FRPH
- DCTH Strong Buy
- Analyst Count
- FRPH 0
- DCTH 4
- Target Price
- FRPH N/A
- DCTH $22.25
- AVG Volume (30 Days)
- FRPH 26.2K
- DCTH 356.0K
- Earning Date
- FRPH 03-05-2025
- DCTH 03-06-2025
- Dividend Yield
- FRPH N/A
- DCTH N/A
- EPS Growth
- FRPH 45.62
- DCTH N/A
- EPS
- FRPH 0.40
- DCTH N/A
- Revenue
- FRPH $31,414,000.00
- DCTH $22,644,000.00
- Revenue This Year
- FRPH N/A
- DCTH $1,672.40
- Revenue Next Year
- FRPH N/A
- DCTH $116.33
- P/E Ratio
- FRPH $76.89
- DCTH N/A
- Revenue Growth
- FRPH 4.04
- DCTH 945.91
- 52 Week Low
- FRPH $26.99
- DCTH $3.70
- 52 Week High
- FRPH $33.00
- DCTH $16.97
- Technical
- Relative Strength Index (RSI)
- FRPH 48.40
- DCTH 46.47
- Support Level
- FRPH $31.07
- DCTH $15.50
- Resistance Level
- FRPH $31.66
- DCTH $16.43
- Average True Range (ATR)
- FRPH 0.59
- DCTH 0.72
- MACD
- FRPH -0.02
- DCTH -0.25
- Stochastic Oscillator
- FRPH 38.02
- DCTH 2.79
About FRPH FRP Holdings Inc.
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, warehouse, and office buildings either alone or through joint ventures (the Development Segment); ownership, leasing and management of buildings through joint ventures (the Multifamily Segment).
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.